Other (please specify) - 1 - Average number of 5.76 5.62 6.60 mentions Q9. Do you think there are any potential benefits to you prescribing/dispensing biosimilar medicines? MULTIPLE RESPONSE The figure below provides details of statistically significant sub-group differences. Figure 27: Benefits to prescribing/dispensing biosimilar medicines sub group differences – Specialists General Practitioners Community pharmacists Rheumatologists were less GPs confident switching a Pharmacists who had likely than other specialists patient to biosimilar dispensed biosimilar to mention potential medicines were more likely medicines were more likely benefits such as to mention taxpayers to mention affordable ‘more ‘save ‘more affordable for (68%). for (74%). hospitals’ money’ patients’ (58%), affordable for ‘more Pharmacists who were patients’ (31%), ‘enables familiar with biosimilar more medicines to be listed medicines were more likely on the PBS’ (42%) to mention patient outcomes against medicine ‘mitigates overall (83%), particularly (11%). shortages’ against medicine ‘mitigate Specialists who were (61%). They shortages’ confident switching a were also more likely to patient to biosimilar mention profit margin ‘larger (70%). medicines were more likely for pharmacies’ to mention: affordable for ‘More hospitals’ (81%) affordable for ‘More (68%) patients’ Benefits to patient outcomes overall (68%), particularly ‘mitigate against medicine (37%), and shortages’ impact on ‘positive patient outcomes’ (23%). Benefits related to industry outcomes overall (28%), specifically ‘improved manufacturing (13%). processes’
Other (please specify) - 1 - Average number of mentions 5.76 5.62 6.60 Q9. Do you think there are any potential benefits to you prescribing/dispensing biosimilar medicines? MULTIPLE RESPONSE The figure below provides details of statistically significant sub-group differences. Figure 27: Benefits to prescribing/dispensing biosimilar medicines – sub group differences Specialists General Practitioners Community pharmacists Rheumatologists were less likely than other specialists to mention potential benefits such as ‘more affordable for hospitals’ (58%), ‘more affordable for patients’ (31%), ‘enables more medicines to be listed on the PBS’ (42%) ‘mitigates against medicine shortages’ (11%). Specialists who were confident switching a patient to biosimilar medicines were more likely to mention: ‘More affordable for hospitals’ (81%) ‘More affordable for patients’ (68%) Benefits to patient outcomes overall (68%), particularly ‘mitigate against medicine shortages’ (37%), and ‘positive impact on patient outcomes’ (23%). Benefits related to industry outcomes overall (28%), specifically ‘improved manufacturing processes’ (13%). GPs confident switching a patient to biosimilar medicines were more likely to mention ‘save taxpayers money’ (68%). Pharmacists who had dispensed biosimilar medicines were more likely to mention ‘more affordable for patients’ (74%). Pharmacists who were familiar with biosimilar medicines were more likely to mention patient outcomes overall (83%), particularly ‘mitigate against medicine shortages’ (61%). They were also more likely to mention ‘larger profit margin for pharmacies’ (70%).